| 16th Oct 2025 7:00 am |
RNS |
Further progress in Phase I/IIa PROTECT trial |
| 31st Jul 2025 7:00 am |
RNS-R |
Grass MATA MPL Publications in Allergy Journal |
| 21st Jul 2025 7:00 am |
RNS |
Trading update for the year ended 30 June 2025 |
| 11th Jul 2025 7:00 am |
RNS |
PDMR Dealings |
| 13th Jun 2025 7:00 am |
RNS-R |
Allergy Therapeutics presents findings at EAACI |
| 10th Jun 2025 7:04 am |
RNS-R |
EAACI Early Career Research Award |
| 31st Mar 2025 7:00 am |
RNS |
Interim Results for six months ended 31 Dec 2024 |
| 27th Mar 2025 7:00 am |
RNS |
Advancement to final phase of PROTECT trial |
| 3rd Mar 2025 7:00 am |
RNS |
New Executive Long Term Incentive Awards |
| 27th Feb 2025 7:00 am |
RNS-R |
Presentations at 2025 AAAAI / WAO Joint Congress |
| 17th Feb 2025 7:00 am |
RNS |
Grass MATA MPL Phase III data published in Allergy |
| 14th Feb 2025 7:00 am |
RNS |
Grant of Options |
| 28th Jan 2025 7:00 am |
RNS |
Half Year Trading update |
| 22nd Jan 2025 7:00 am |
RNS |
PDMR Dealing and Total Voting Rights |
| 15th Jan 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
| 19th Dec 2024 1:41 pm |
RNS |
Exercise of Options and Total Voting Rights |
| 17th Dec 2024 4:19 pm |
RNS |
Block Listing Interim Review |
| 16th Dec 2024 3:33 pm |
RNS |
Result of Annual General Meeting |
| 4th Dec 2024 7:00 am |
RNS |
Positive Interim Data from PROTECT Trial |
| 27th Nov 2024 7:00 am |
RNS |
First Patient Dosed in G308 Paediatric Trial |
| 25th Nov 2024 7:00 am |
RNS |
Submission of MAA for Grass MATA MPL |
| 21st Nov 2024 7:00 am |
RNS |
Notice of 2024 Annual General Meeting |
| 6th Nov 2024 7:00 am |
RNS |
Audited Preliminary Results 2024 |
| 21st Oct 2024 7:00 am |
RNS |
Commencement of Phase III Paediatric Trial |
| 16th Oct 2024 7:00 am |
RNS |
Update on funding |
| 1st Oct 2024 7:00 am |
RNS |
Update on funding and preliminary results |
| 17th Sep 2024 7:00 am |
RNS |
Progression of patient cohorts in PROTECT Trial |
| 27th Aug 2024 7:00 am |
RNS |
Update on funding |
| 22nd Jul 2024 7:01 am |
RNS |
Trading update for the year ended 30 June 2024 |
| 22nd Jul 2024 7:00 am |
RNS |
Appointment of Nominated Adviser and Sole Broker |
| 4th Jul 2024 2:22 pm |
RNS |
Launch of new Company Long Term Incentive Plan |
| 27th Jun 2024 7:00 am |
RNS |
Appointment of Non-Executive Director |
| 10th Jun 2024 7:00 am |
RNS |
Progression of patient cohorts in PROTECT Trial |
| 3rd Jun 2024 7:00 am |
RNS |
Successful meetings with Paul Ehrlich Institut |
| 31st May 2024 7:00 am |
RNS |
Allergy Therapeutics presents findings at EAACI |
| 7th May 2024 7:00 am |
RNS |
Further detail from G306 Phase III field trial |
| 3rd Apr 2024 7:00 am |
RNS |
Director Resignation |
| 27th Mar 2024 7:00 am |
RNS |
Update on funding |
| 27th Mar 2024 7:00 am |
RNS |
Interim Results for six months ended 31 Dec 2023 |
| 12th Mar 2024 8:59 am |
RNS |
VLP Peanut PROTECT Trial Update |
